title: Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis.
abstract: Chronic respiratory tract infections caused by Staphylococcus aureus are common in patients with cystic fibrosis (CF). Recently, it was shown in a few CF patients that S. aureus isolates produce capsular polysaccharides (CPs). However, it is not known whether this is a common feature and whether an immune response to CPs in CF is detectable. Therefore, we examined 170 S. aureus isolates from CF patients and healthy individuals for production of CP types 5 and 8 by using monoclonal antibodies. We found that CP-producing staphylococcal isolates were randomly distributed among CF patients and healthy carriers. Eighty-five percent of all isolates produced CPs, 77% of which were type 8. Examination of one sputum sample by an immunofluorescence technique suggested that production of CPs is not an in vitro phenomenon. S. aureus isolates from various sites of a single person often yielded more than one CP type. A random distribution of S. aureus strains with CP type 5 or 8 from the skin and respiratory tracts of patients and from the skin of healthy individuals was found. Antibody response to CP types 5 and 8, measured by enzyme-linked immunosorbent assay, was not elevated in CF patients with chronic S. aureus lung infection in comparison with healthy carriers. On the contrary, in CF patients the ratios of antibodies to CP 8 were significantly lower (P less than 0.005; alpha = 0.025). The ratios of antibodies to CP types did not change when monitored longitudinally over several months. This study suggests that the production of CPs is a universal property of S. aureus and that infected CF patients do not have elevated ratios of antibodies to these antigens.
authors.affiliation: Hygiene-Institute, University of Tübingen, Federal Republic of Germany.
authors.forename: A
authors.initials: A
authors.lastname: Albus
authors.forename: J M
authors.initials: JM
authors.lastname: Fournier
authors.forename: C
authors.initials: C
authors.lastname: Wolz
authors.forename: A
authors.initials: A
authors.lastname: Boutonnier
authors.forename: M
authors.initials: M
authors.lastname: Ranke
authors.forename: N
authors.initials: N
authors.lastname: Høiby
authors.forename: H
authors.initials: H
authors.lastname: Hochkeppel
authors.forename: G
authors.initials: G
authors.lastname: Döring
mesh_terms: D000907:Antibodies, Bacterial / Q000032:analysis*; D000911:Antibodies, Monoclonal; D000917:Antibody Formation; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications / Q000276:immunology*; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000209:etiology / Q000276:immunology / Q000382:microbiology*; D008297:Male; D011135:Polysaccharides, Bacterial / Q000032:analysis / Q000276:immunology; D012016:Reference Values; D013203:Staphylococcal Infections / Q000209:etiology / Q000276:immunology*; D013211:Staphylococcus aureus / Q000276:immunology* / Q000302:isolation & purification
chemical_list: D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D011135:Polysaccharides, Bacterial